Phase II study of tivantinib (ARQ 197) and cetuximab in patients with EGFR inhibitor-resistant, MET-High, KRAS wild-type (KRASwt) metastatic colorectal cancer (mCRC)

被引：0
|
作者：
Lorenza, Rimassa [1 ]
Silvia, Bozzarelli [1 ]
Stefano, Cordio [2 ]
Filippo, Pietrantonio [3 ]
Laura, Toppo [4 ]
Sara, Lonardi [5 ]
Alberto, Zaniboni [6 ]
Roberto, Bordonaro [7 ]
Maria, Di Bartolomeo [8 ]
Wanda, Liguigli [4 ]
Vittorina, Zagonel [5 ]
Chiara, Tronconi Maria [1 ]
Luca, Di Tommaso [9 ]
Laura, Giordano [1 ]
Armando, Santoro [1 ]
机构：
[1] Ist Clin Humanitas IRCCS, Humanitas Canc Ctr, Rozzano, Italy
[2] Garibaldi Nesima Hosp, Dept Oncol, Catania, Italy
[3] Fdn IRCCS Ist Nazl Tumori, Milan, Italy
[4] Ist Ospitalieri Cremona, Struttura Complessa Oncol, Cremona, Italy
[5] Ist Oncol Veneto IRCCS, Oncol Med 1, Padua, Italy
[6] Fdn Poliambulanza, Brescia, Italy
[7] Osped Garibaldi, Unita Oncol Med, Catania, Italy
[8] Fdn IRCCS Ist Nazl Tumori, Dept Oncol, Milan, Italy
[9] Ist Clin Humanitas IRCCS, Dept Pathol, Rozzano, Italy
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD - 028
引用
收藏
页数：1
相关论文
共 50 条
  • [1] ONC-2012-001: A single-arm phase II study of tivantinib (ARQ 197) plus cetuximab in EGFR inhibitor-resistant MET high patients (pts) with locally advanced or metastatic colorectal cancer (CRC) with wild-type KRAS.
    Rimassa, Lorenra
    Bozzarelli, Silvia
    Zaniboni, Alberto
    Foa, Paolo
    Carnaghi, Carlo
    Passalacqua, Rodolfo
    Ramello, Monica
    Di Tommaso, Luca
    Glordano, Laura
    Sanboro, Armando
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] PHASE I/II STUDY OF TIVANTINIB (ARQ 197) IRINOTECAN, AND CETUXIMAB IN PATIENTS WITH KRAS WILDTYPE, PREVIOUSLY TREATED, METASTATIC COLORECTAL CANCER
    Eng, Cathy
    Alberto, Bessudo
    Gabrail, Nashat
    Lopez, Taina
    Zahir, Hamim
    von Roemeling, Reinhard
    Bendell, Johanna
    ANNALS OF ONCOLOGY, 2012, 23 : 24 - 25
  • [3] Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition
    Rimassa, Lorenza
    Bozzarelli, Silvia
    Pietrantonio, Filippo
    Cordio, Stefano
    Lonardi, Sara
    Toppo, Laura
    Zaniboni, Alberto
    Bordonaro, Roberto
    Di Bartolomeo, Maria
    Tomasello, Gianluca
    Dadduzio, Vincenzo
    Tronconi, Maria Chiara
    Piombo, Chiara
    Giordano, Laura
    Gloghini, Annunziata
    Di Tommaso, Luca
    Santoro, Armando
    CLINICAL COLORECTAL CANCER, 2019, 18 (02) : 125 - +
  • [4] A phase Ib study of AUY922 and cetuximab in patients with KRAS wild-type (WT) metastatic colorectal cancer (mCRC).
    Subramaniam, Somasundaram
    Goodman, Gary E.
    Boatman, Barry
    Smith, Andrew W.
    Iriarte, Desiree
    Gold, Philip Jordan
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [5] Phase II study of cetuximab with irinotecan for KRAS wild-type colorectal cancer in Japanese patients
    Terazawa, Tetsuji
    Nishitani, Hitoshi
    Kato, Ken
    Hashimoto, Hironobu
    Akiyoshi, Kohei
    Ito, Yuriko
    Nakamoto, Akihiro
    Iwasa, Satoru
    Nakajima, Takako Eguchi
    Hamaguchi, Tetsuya
    Yamada, Yasuhide
    Shimada, Yasuhiro
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2017, 13 (02) : E132 - E137
  • [6] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [7] Retrospective evaluation of ADCC activity and cetuximab response in KRAS wild-type metastatic colorectal cancer patients (mCRC)
    Miraglio, E.
    Ricci, V.
    Vivenza, D.
    Monteverde, M.
    Strola, G.
    Granetto, C.
    Lo Nigro, C.
    Merlano, M. C.
    ANNALS OF ONCOLOGY, 2015, 26 : 40 - 40
  • [8] Phase II single-arm study of palbociclib and cetuximab rechallenge in KRAS/NRAS/BRAF wild-type (KRAS WT) metastatic colorectal cancer (mCRC) patients (pts)
    Sorah, Jonathan D.
    Moore, Dominic T.
    Reilley, Matthew
    Salem, Mohamed E.
    Sanoff, Hanna Kelly
    Triglianos, Tammy
    McRee, Autumn Jackson
    Lee, Michael Sangmin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [9] A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy
    Eng, Cathy
    Bessudo, Alberto
    Hart, Lowell L.
    Severtsev, Aleksey
    Gladkov, Oleg
    Mueller, Lothar
    Kopp, Mikhail V.
    Vladimirov, Vladimir
    Langdon, Robert
    Kotiv, Bogdan
    Barni, Sandro
    Hsu, Ching
    Bolotin, Ellen
    von Roemeling, Reinhard
    Schwartz, Brian
    Bendell, Johanna C.
    INTERNATIONAL JOURNAL OF CANCER, 2016, 139 (01) : 177 - 186
  • [10] PANITUMUMAB AFTER PROGRESSION ON CETUXIMAB IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC): A SINGLE INSTITUTION EXPERIENCE
    Marino, Antonella
    Caliolo, Chiara
    Sponziello, Francesco
    Nacci, Angelo
    Quaranta, Annamaria
    Mazzoni, Enrica
    Rizzo, Pietro
    Calvani, Nicola
    Orlando, Laura
    Schiavone, Paola
    Fedele, Palma
    D'Amico, Maria
    Cinefra, Margherita
    Cinieri, Saverio
    ANNALS OF ONCOLOGY, 2012, 23 : 95 - 96
12345